文献速递消化系统肿瘤

结直肠癌微小残留病灶:肿瘤信息依赖与肿瘤信息无关策略的比较——探寻最优策略

Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.
PubMed 文献 · Ann Oncol · 2024-12-13

本综述汇总截至2024年11月发表的研究,比较肿瘤信息依赖与肿瘤信息无关两种ctDNA策略在结直肠癌微小残留病灶检测中的效用与性能。两种策略均可用于术后风险分层和辅助化疗决策;肿瘤信息依赖策略的复发预测敏感性和特异性通常更优,但需先做组织测序且成本更高;肿瘤信息无关策略仅依赖血浆分析、适用面更广,但敏感性相对较低。

要点

  • 肿瘤信息依赖策略复发预测的敏感性和特异性通常更优,但需先行组织测序且成本更高。
  • 肿瘤信息无关策略仅依赖血浆分析、适用面更广,但敏感性相对较低。
  • 片段组学与多组学整合等新技术正在提升两种策略的检测能力。

核心结论

  • 肿瘤信息依赖策略目前在MRD检测中精度更高,肿瘤信息无关策略因便捷且性能指标不断改善而受到越来越多关注。
  • 正在进行的临床试验整合新技术后,可能重新定义结直肠癌MRD检测的最优策略,推动更个性化和自适应的患者管理。

研究设计与样本

  • 本综述汇总截至2024年11月发表的研究,探讨肿瘤信息依赖与肿瘤信息无关两种ctDNA分析方法在结直肠癌中的效用与性能。
  • 作者评估两种方法各自的优势与局限,重点关注敏感性、特异性和临床结局。

主要发现

  • 两种策略在结直肠癌患者术后风险分层和指导辅助化疗决策方面均显示出临床效用。
  • 肿瘤信息依赖方法因采用个性化肿瘤图谱设计,在复发预测方面通常表现出更优的敏感性和特异性。
  • 肿瘤信息依赖方法受限于需要预先进行组织测序且相关成本更高。
  • 肿瘤信息无关方法因仅依赖血浆分析而适用面更广,但敏感性相对较低。
  • 片段组学和多组学整合等技术进步正在拓展ctDNA-based MRD检测的能力,提升两种方法的性能。

局限性

  • 肿瘤信息依赖方法受限于需要预先进行组织测序且相关成本更高。
  • 肿瘤信息无关方法虽适用面更广,但敏感性相对较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive tool for detecting minimal residual disease (MRD) in colorectal cancer (CRC) patients. This enables dynamic risk stratification, earlier recurrence detection and optimized post-surgical treatment. Two primary methodologies have been developed for ctDNA-based MRD detection: tumor-informed strategies, which identify tumor-specific mutations through initial tissue sequencing to guide ctDNA monitoring, and tumor-agnostic approaches, which utilize predefined panels to detect common cancer-associated genomic or epigenomic alterations directly from plasma without prior tissue analysis. The debate over which is superior in terms of sensitivity, specificity, cost-effectiveness and clinical feasibility remains unsolved. DESIGN: This review summarizes studies published up to November 2024, exploring the utility and performance of tumor-informed and tumor-agnostic approaches for ctDNA analysis in CRC. We evaluate the strengths and limitations of each methodology, focusing on sensitivity, specificity and clinical outcomes. RESULTS: Both strategies demonstrate clinical utility in post-operative risk stratification and guiding adjuvant chemotherapy decisions in CRC patients. Tumor-informed approaches generally exhibit superior sensitivity and specificity for recurrence prediction, attributed to their personalized tumor profile designs. However, these methods are limited by the need for prior tissue sequencing and higher associated costs. In contrast, tumor-agnostic approaches offer broader applicability due to their reliance on plasma-only analysis, although with relatively lower sensitivity. Technological advancements, including fragmentomics and multi-omic integrations, are expanding the capabilities of ctDNA-based MRD detection, enhancing the performance of both approaches. CONCLUSIONS: While tumor-informed strategies currently offer higher precision in MRD detection, tumor-agnostic approaches are gaining traction due to their convenience and improving performance metrics. The integration of novel technologies in ongoing clinical trials may redefine the optimal approach for MRD detection in CRC, paving the way for more personalized and adaptive patient management strategies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Martínez-Castedo B, Camblor DG, Martín-Arana J, et al. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Ann Oncol. 2024. PMID: 39675560. doi:10.1016/j.annonc.2024.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。